A. Chakrabarti, S. S. Chatterjee, and A. Das, Invasive zygomycosis in India: experience in a tertiary care hospital, Postgrad Med J, vol.85, pp.573-81, 2009.

F. Lanternier, E. Dannaoui, and G. I. Morizot, A global analysis of mucormycosis in France: the RetroZygo Study, Clin Infect Dis, vol.54, issue.1, pp.35-43, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00818503

M. J. Ruping, W. J. Heinz, and A. J. Kindo, Forty-one recent cases of invasive zygomycosis from a global clinical registry, J Antimicrob Chemother, vol.65, pp.296-302, 2010.

A. Skiada, L. Pagano, and A. Groll, Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between, Clin Microbiol Infect, vol.17, pp.1859-67, 2005.

D. P. Kontoyiannis, N. Azie, and B. Franks, Prospective Antifungal Therapy (PATH) Alliance w : focus on mucormycosis, Mycoses, vol.57, pp.240-246, 2014.

V. Saegeman, J. Maertens, and W. Meersseman, Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis, vol.16, pp.1456-1464, 2010.

R. Ben-ami, M. Luna, and R. E. Lewis, A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response, J Infect, vol.59, pp.134-142, 2009.

R. G. Vitale, G. S. De-hoog, and P. Schwarz, Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales, J Clin Microbiol, vol.50, pp.66-75, 2012.

S. Perkhofer, V. Lechner, and C. Lass-florl, In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing, Antimicrob Agents Chemother, vol.53, pp.1645-1652, 2009.

B. Spellberg, A. S. Ibrahim, and P. V. Chin-hong, The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, doubleblinded, placebo-controlled trial, J Antimicrob Chemother, vol.67, pp.715-737, 2012.

F. Marty, J. Perfect, and O. Cornely, An open-label phase 3 study of isavuconazole (VITAL): focus on mucormycosis, 2014.

A. Nosari, P. Oreste, and M. Montillo, Mucormycosis in hematologic malignancies: an emerging fungal infection, Haematologica, vol.85, pp.1068-71, 2000.

L. Pagano, M. Offidani, and L. Fianchi, Mucormycosis in hematologic patients, Haematologica, vol.89, pp.207-221, 2004.

D. P. Kontoyiannis, V. C. Wessel, and G. P. Bodey, Zygomycosis in the 1990s in a tertiary-care cancer center, Clin Infect Dis, vol.30, pp.851-857, 2000.

R. Herbrecht, V. Letscher-bru, and R. A. Bowden, Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion, Eur J Clin Microbiol Infect Dis, vol.20, pp.460-466, 2001.

M. M. Roden, T. E. Zaoutis, and W. L. Buchanan, Epidemiology and outcome of zygomycosis: a review of 929 reported cases, Clin Infect Dis, vol.41, pp.634-53, 2005.

S. Shoham, S. S. Magill, and W. G. Merz, Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases, Med Mycol, vol.48, pp.511-518, 2010.

R. E. Lewis, N. D. Albert, and G. Liao, Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis, Antimicrob Agents Chemother, vol.54, pp.1298-304, 2010.

T. J. Walsh, J. L. Goodman, and P. Pappas, Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study, Antimicrob Agents Chemother, vol.45, pp.3487-96, 2001.

V. Syriopoulou, G. L. Daikos, and M. Theodoridou, Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis, Clin Infect Dis, vol.36, pp.560-566, 2003.

O. A. Cornely, J. Maertens, and M. Bresnik, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial), Clin Infect Dis, vol.44, pp.1289-97, 2007.

B. De-pauw, T. J. Walsh, and J. P. Donnelly, Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, Clin Infect Dis, vol.46, pp.1813-1834, 2008.

R. Herbrecht, D. W. Denning, and T. F. Patterson, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, vol.347, pp.408-423, 2002.

B. H. Segal, R. Herbrecht, and D. A. Stevens, Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria, Clin Infect Dis, vol.47, pp.674-83, 2008.

A. Chowdhary, S. Kathuria, and P. K. Singh, Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, Mycoses, vol.57, issue.3, pp.97-107, 2014.

A. Xhaard, F. Lanternier, and R. Porcher, Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study, Clin Microbiol Infect, vol.18, pp.396-400, 2003.

K. A. Marr, H. T. Schlamm, and R. Herbrecht, Combination antifungal therapy for invasive aspergillosis: a randomized trial, Ann Intern Med, vol.162, pp.81-90, 2015.

D. Caillot, V. Latrabe, and A. Thiebaut, Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials, Eur J Radiol, vol.74, pp.172-177, 2010.

C. Legouge, D. Caillot, and M. L. Chretien, The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?, Clin Infect Dis, vol.58, pp.672-680, 2014.